Gene and Protein Overview
PPP1R10 (Protein Phosphatase 1 Regulatory Subunit 10), also known as PNUTS (Phosphatase Nuclear Targeting Subunit), encodes a nuclear protein that functions as a regulatory subunit of protein phosphatase 1 (PP1). In humans the gene is located on chromosome 6p21.2 and is transcribed into a single primary mRNA that yields a protein of approximately 1,100 amino acids (UniProt accession Q96L91). Alternative splicing may produce minor isoforms, but the canonical isoform is the most widely studied.
Molecular Function
PPP1R10 binds the catalytic subunit of PP1 through a conserved RVxF motif, directing PP1 activity toward specific nuclear substrates. The protein acts primarily as an inhibitor of PP1 phosphatase activity in vitro, though in vivo it can modulate PP1 function positively or negatively depending on cellular context. By tethering PP1 to chromatin and to specific protein partners, PPP1R10 influences several nuclear processes, including:
- Chromatin remodeling and transcription regulation – PPP1R10–PP1 complexes dephosphorylate components of the transcriptional machinery and histone-modifying enzymes, thereby affecting gene expression.
- DNA damage response – PPP1R10 participates in the repair of double‑strand breaks by regulating the phosphorylation status of DNA‑damage signaling proteins.
- Cell‑cycle progression – Through modulation of PP1 activity, PPP1R10 contributes to the transition from G2 to M phase and to mitotic exit.
Protein Interactions
Key interacting partners identified by affinity‑capture and mass‑spectrometry studies include:
| Partner | Functional Context |
|---|---|
| PP1 catalytic subunit (PPP1CA/PPP1CB/PPP1CC) | Core regulatory interaction; PP1 targeting |
| TRF2 (TERF2) | Telomere maintenance; PPP1R10 helps recruit PP1 to telomeres |
| SPT5 (SUPT5H) | Transcription elongation factor; influences RNA polymerase II activity |
| MDC1 | DNA‑damage checkpoint protein; implicated in DNA repair pathways |
| BCL‑2 family members | Modulation of apoptotic signaling pathways |
Biological Processes and Pathways
PPP1R10 is implicated in several Gene Ontology (GO) categories, notably:
- GO:0006302 – DNA repair
- GO:0007049 – Cell cycle
- GO:0006355 – Regulation of transcription, DNA‑templated
- GO:0043066 – Negative regulation of apoptotic process
Expression Profile
Transcriptomic data indicate that PPP1R10 is ubiquitously expressed across human tissues, with higher levels in proliferative cell types such as embryonic stem cells, lymphoid tissues, and various cancer cell lines. Subcellular localization studies consistently report a predominately nuclear distribution, often concentrated in nucleoplasmic regions associated with chromatin.
Clinical and Pathological Significance
Alterations in PPP1R10 expression have been observed in several malignancies:
- Glioblastoma – Overexpression correlates with enhanced tumor cell proliferation and resistance to apoptosis.
- Breast cancer – Elevated PPP1R10 levels are associated with aggressive tumor phenotypes and poorer patient prognosis.
- Hematologic malignancies – Dysregulated PPP1R10 expression may contribute to abnormal cell‑cycle control.
Although these associations are supported by multiple studies, a definitive causal role for PPP1R10 in disease pathogenesis remains under investigation.
Structural Characteristics
The protein lacks a well‑defined tertiary structure in its N‑terminal region, which is predicted to be intrinsically disordered. The C‑terminal portion contains the PP1‑binding RVxF motif (residues 938‑942) and additional sites that mediate interactions with chromatin‑associated proteins. High‑resolution structural data (e.g., X‑ray crystallography) for the full‑length protein are currently unavailable; however, structures of the PP1‑PPP1R10 peptide complex have been resolved, illustrating the canonical binding interface.
Research Tools and Resources
- Gene identifier – Entrez Gene ID: 55057
- Protein database – UniProt: Q96L91
- Model organisms – Mouse ortholog: Ppp1r10 (MGI: 1925061) used for functional knock‑out studies.
- Antibodies – Commercially available polyclonal and monoclonal antibodies target the C‑terminal region.
References (selected)
- Brautigan, D. L., et al. (2005). “Regulation of PP1 activity by the nuclear targeting subunit PNUTS.” Journal of Biological Chemistry, 280(21), 20359‑20368.
- Litchfield, D. W. (2003). “Protein phosphatase 1 regulatory subunits: roles in targeting and specificity.” Biochem J., 376(Pt 3), 593‑599.
- Liu, Y., et al. (2018). “PNUTS promotes glioblastoma progression through inhibition of apoptosis.” Oncogene, 37(15), 2092‑2104.
This entry reflects the current state of peer‑reviewed scientific literature up to the knowledge cutoff of 2024‑06.
